前列腺癌与遗传因素
Prostate cancer and genetic contributions.
作者信息
Chou Wesley H, Chalker Cameron, Sokolova Alexandra O, Isharwal Sudhir
机构信息
Department of Urology, Oregon Health & Sciences University, Portland, Oregon, USA.
Division of Hematology/Medical Oncology, School of Medicine, Oregon Health & Sciences University, Portland, Oregon, USA.
出版信息
Andrology. 2024 Nov 29. doi: 10.1111/andr.13812.
Abstract
Prostate cancer remains a lethal disease for many men. Knowledge of genetic contributions to this condition has increasingly been used in its management. In this narrative review, we summarize various genetic alterations and syndromes associated with prostate cancer, including hereditary breast and ovarian cancer syndrome, Lynch syndrome, and hereditary prostate cancer, among others. Indications for germline testing are reviewed, as well as incorporation of genetic data at different phases of management for prostate cancer, such as screening and monitoring, and treatment of localized and metastatic disease.
摘要
前列腺癌对许多男性来说仍然是一种致命疾病。对这种疾病的遗传因素的了解越来越多地应用于其治疗中。在这篇叙述性综述中，我们总结了与前列腺癌相关的各种基因改变和综合征，包括遗传性乳腺癌和卵巢癌综合征、林奇综合征以及遗传性前列腺癌等。我们还综述了种系检测的指征，以及在前列腺癌治疗的不同阶段（如筛查和监测、局限性和转移性疾病的治疗）纳入基因数据的情况。
相似文献
1
Prostate cancer and genetic contributions.前列腺癌与遗传因素
Andrology. 2024 Nov 29. doi: 10.1111/andr.13812.
2
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.前列腺癌中的胚系突变：个性化医学证据的系统评价。
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):655-664. doi: 10.1038/s41391-022-00609-3. Epub 2022 Nov 24.
3
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.将通用种系基因检测纳入前列腺癌患者的标准治疗：时机已到。
JCO Oncol Pract. 2025 Jun;21(6):747-753. doi: 10.1200/OP-24-00626. Epub 2024 Dec 19.
4
Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.结直肠癌患者林奇综合征的分子检测：系统评价和经济评估。
Health Technol Assess. 2017 Sep;21(51):1-238. doi: 10.3310/hta21510.
5
Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes-A systematic review.X型家族性结直肠癌（FCCTX）及其与多种基因的相关性——一项系统综述
Curr Probl Cancer. 2017 Nov-Dec;41(6):388-397. doi: 10.1016/j.currproblcancer.2017.10.002. Epub 2017 Oct 18.
6
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.林奇综合征遗传易感性个体的护理建议：一项系统综述
JAMA. 2006 Sep 27;296(12):1507-17. doi: 10.1001/jama.296.12.1507.
7
Chemotherapy for hormone-refractory prostate cancer.激素难治性前列腺癌的化疗
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005247. doi: 10.1002/14651858.CD005247.pub2.
8
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.双膦酸盐或 RANK 配体抑制剂治疗前列腺癌伴骨转移的男性患者：一项网状荟萃分析。
Cochrane Database Syst Rev. 2020 Dec 3;12(12):CD013020. doi: 10.1002/14651858.CD013020.pub2.
9
Cryotherapy for localised prostate cancer.局部前列腺癌的冷冻疗法。
Cochrane Database Syst Rev. 2007 Jul 18(3):CD005010. doi: 10.1002/14651858.CD005010.pub2.
10
Analysis of the conditions for applying BRCA genetic testing to women with breast cancer using the Japanese HBOC consortium and the Japanese organization of hereditary breast and ovarian cancer (JOHBOC) registry project database.利用日本遗传性乳腺癌和卵巢癌联盟（HBOC）以及日本遗传性乳腺癌和卵巢癌组织（JOHBOC）登记项目数据库，分析对乳腺癌女性应用BRCA基因检测的条件。
Breast Cancer. 2025 May 5. doi: 10.1007/s12282-025-01704-8.
引用本文的文献
1
The rising role of genetics in andrology research and clinical practice.遗传学在男科研究与临床实践中日益重要的作用。
Andrology. 2025 Jul;13(5):983-985. doi: 10.1111/andr.70073.
本文引用的文献
1
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer.去势抵抗性前列腺癌中雄激素受体降解的最新进展洞察
Cancers (Basel). 2024 Feb 4;16(3):663. doi: 10.3390/cancers16030663.
2
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.阿比特龙联合奥拉帕利治疗转移性去势抵抗性前列腺癌
NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3.
3
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.《前列腺癌（第四版）》，2023 年，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050.
4
Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.美国医疗保险人群中转移性去势抵抗性前列腺癌（mCRPC）男性的真实世界治疗模式和总生存情况。
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):327-333. doi: 10.1038/s41391-023-00725-8. Epub 2023 Oct 2.
5
PARP inhibitors: enhancing efficacy through rational combinations.PARP 抑制剂：通过合理联合增强疗效。
Br J Cancer. 2023 Oct;129(6):904-916. doi: 10.1038/s41416-023-02326-7. Epub 2023 Jul 10.
6
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.泰拉唑帕尼联合恩扎卢胺治疗一线转移性去势抵抗性前列腺癌（TALAPRO-2）：一项随机、安慰剂对照、III 期临床试验。
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
7
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.鲁卡帕利治疗伴有 DNA 损伤修复基因改变的转移性去势抵抗性前列腺癌：来自 II 期 TRITON2 研究的最终结果。
Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3.
8
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).《晚期前列腺癌更新：AUA/SUO 指南（2023）》。
J Urol. 2023 Jun;209(6):1082-1090. doi: 10.1097/JU.0000000000003452. Epub 2023 Apr 25.
9
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.早期前列腺癌检测：AUA/SUO 指南第 I 部分：前列腺癌筛查。
J Urol. 2023 Jul;210(1):46-53. doi: 10.1097/JU.0000000000003491. Epub 2023 Apr 25.
10
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.尼拉帕利与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌。
J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23.
Zotero 插件